Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
We help save lives by improving verbal and written communications that occur betwe...
We help save lives by improving verbal and writ...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug develo...
Phoenix PharmaLabs, Inc. (PPL) is a privately h...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...
Headquartered in Mountain View, California, IGM...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
We are a clinical-stage immuno-oncology company specializing in the development an...
We are a clinical-stage immuno-oncology company...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Join the National Investor Network and get the latest information with your interests in mind.